

REFERENCES

- Aiello, L.M. and Cavallerano, J.: (1994):** Diabetic retinopathy Curr Their Endocrinol metab. 5: 436-46.
- Aiello, L.P. and Cahilli, M.T. (2001):** Systemic considerations in the management of diabetic retinopathy. American Journal of Ophthalmoloty. 132, 740-776.
- Albert, D.M. (2000)::** Diabetic macular edema. Arch Ophthalmol. 119(1): 13-15.
- Albrecht, E.W.; Stegeman, C.A.; Heeringa, P.; Henning, R.H.; et al (2003):** Protective role of endothelial nitric oxide synthase. J Pathol. 199: 8-17.
- Antcliff, R.J. and Marshall, J. (1999):** The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol.1999; 14: 233-232.
- Arevalo, J.F.; Fromow-Guerra, J.; Quiroz-Mercado, H.; et al. (2007)** :Primary intavitreal bevacizumab (Avastin)_ for diabetic macular edema. Ophthalmology 114:743-750.
- Avci, R.; Kaderli, B. and Akalp, F.D. (2006):** Intravitreal triamcinolone injection for chronic diffuse diabetic macular edema. Clinical and Experimental Ophthalmology 34: 27-32.
- Avery, R.I.; Pearlman, J.; Pieramici, D.J.; et al: (2006):** Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthamology, 113:1695-17.
- Avitabile, T.; Longo, A. and Reibaldi, A. (2005):** Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol, 140: 695-702.
- Bakri, S.J. and Beer, P.M. (2003):** The effect of intravitreal triamcinolone acetate on intraocular pressure. Ophthalmic Surg Lasers imaging. 34 (5): 386-390.
- Barber, and Lieth (2000):** Retinal neurodegeneration, early pathology in diabetes. Clin Experiment Ophthalmol. 2000 Feb; 28(1): 3-8.

- Beer, P.M.; Bakri, S.J.; Singh, R.J.; Liu, W.; et al (2003):** Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. *Ophthalmology*.110: 681-686.
- Ben Hamouda, H.; Messaoud, R.; and Khairallah, M.; et al (2001):** Prevalence and risk factors of diabetic retinopathy in children and young adults. *Ophthalmol.*; 24(4): 367-70.
- Benz, M.S.; Murray, T.G.; Dubovy, S.R.; et al (2003):** Endophthalmitis caused by *Mycobacterium chelonae* abscessus after intravitreal injection of triamcinolone. *Arch Ophthalmol*.121: 271-273.
- Bresnick ,G.H. (1986):** Diabetic macular edema *ophthalmology*.93(7): 989-97.
- Bristol Myers squibb (2001):** Medical communications, Pharmacokinetics of intravitreal bevacizumab (Avastin) *Ophthamology* 114:855-859.
- Brown, D.M.; Kaiser, P.K.; Michels, M. et al (2006):** Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *New England Journal of Medicine*.vol. 355, no14,pp.
- Camera, A. and Hopps, E. (2007):** Diabetic micro-angipathy, Physiopathological, clinical and therapeutic aspects. *Endocrinologica*. 32 (3), 209-229.
- Candorfer, A. and Kampikm, A. (2006):** Surgical removal of the internal limiting membrane in diabetic cystoid macular edema. *Retina*. 26: 485-6.
- Castern, H. and Meyer, C.H. (2007):** Current treatment approaches in diabetic macular edema. *Department of Ophthalmology. Ophthalmologica*. 221: 118-131.
- Catier, A.; Tadayoni, R.; Paques, M.; et al., (2005):** Characterization of macular edema for, various etiologies by optical coherence tomography. *Am J Ophthalmol*. 140:200-0206.

- Cekic, O.; Chang, S. and Akar, Y. (2005):** Cataract progression after intravitreal triamcinolone injection. *Am J Ophthalmol.* 139(6): 993-998.
- Chan, A. and Duker, J.S. (2005):** A standardized method for reporting changes in macular thickening using optical coherence tomography. *Arch Ophthalmol.* 123: 939-43.
- Chan, C.K.; Mohamed, S. and Lam, D.S. (2006):** Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular edema. *Br J Ophthalmol.* 90 (9): 1137-41.
- Chew, E.Y.; Klein, M.L.; Ferris, F.L.; Remaley, N.A.; Murphy, P.; Chantry, K. and Miller, D. (1996):** Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol.* 114(9) 1079-84.
- Chew, E.Y.; Murphy, R.P.; New some, D.A. (1986):** Parafoveal telangectasia and diabetic retinopathy *Arch. Ophthalmol.* 104: 71-75.
- Chun, D.W.; Heier, J.S.; Topping, T.M.; Duker, J.S and Bankert, J.M. (2006):** A pilot study of multiple intravitreal injections of ranibizumab in patients with center involving clinically significant diabetic macular edema, *Ophthalmology.* 2006.vol. 113, no. 10, pp. 1706-1712..
- Ciardella, A.P.; Klancnik, J.; Schiff, W.; et al (2004):** Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates. an optical coherence tomography study. *Br J Ophthalmol.* 88: 1131-6.
- Ciulla, T.A.; Amador, A.G. and Zenman, B. (2003):** Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. *Diabetes care.* 26(9): 2653-64.
- Cunliffe, I.A.; Flanagan DW, George, N.D. and Moore, A.T. (1991):** Extracapsular cataract surgery with lens implantation in diabetics with and without proliferative retinopathy. *Br J ophthalmol.* 75(1): 9-12.

- Cunningham, E.T.; Adamis, A.P.; Altaweel, N.T.; Aiello, L.P.; Bressler, N.M.; D'Amico, D.J.; Goldbaum, M.; Guyer, D.R. Katz, B.; Patel, M. and Schwartz, S.D. (2005):**Macugen Diabetic Retinopathy Study Group: A pahse2 randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology*. 112: 1747-57.
- David, J. Browning (2006):** Vitrectomy Surery as First-Line Treatment for DME: Retinal physicians.
- David, M.K. (1992):** Anatomic correlates of the retina: Duane's clinical ophthalmology, volume 3, chapter 1. Philadelphia: JB Lippincott Company,1.
- Dennis, S.C.; Lam, M.D.; Carmen, K.M.; Chan, Shaheeda Mohamed, Vincent, Y.W.; Lee, David, T.L. Liu, Kenneth, K.W. Li, et al., (2007):** Diabetic Retinopathy. *Ophthalmology*. 59(6): 45-51.
- Desai, V.N.; Duker, J.S. and Puliafito, C.A. (2000):** Optical coherence tomography. Macular surgery. Philadelphia, New York, London, Hong Kong, Sydney: Lippincott Williams and Wilkings, 56-75.
- Diabetic Retinopathy Clinical Research Network (2005)::** A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema.Version 4.
- Diabetic Retinopathy Clinical Research Network (2007):** Relationship between optical coherence tomography measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology*. 114: 525-36.
- Doc, A.; Ramos, P.; Reis, A.; Proenca, R. and Cunna-Vaz, J.G. (1998):** Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. *Exp Eye Res*. 67: 569-575.
- Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) report Number 2 (1987):** Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. *Ophthalmology* . 94: 76.

- Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) Report Number 19 (1995):** Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. Arch Ophthalmol. 113: 1144-55.
- Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) report number 5 (1989):** Detection of diabetic macular edema.. Ophthalmology. 1989; 96: 764-50.
- Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) report number 13 (19914):** Fluorescein angiographic risk factors for progression of diabetic retinopathy. Ophthalmology. 98: 834-840.
- Edelman, J.L.; Lute, D. and Castro, M.R. (2005):** Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 80 (2): 249-58.
- Einar Stefansson, (2006):** Laser Photocoagulation therapy as First-Line treatment for DME. Retinal Phsicans.
- Ferrara, N. (2004):** Vascular endothelial growth factors: basic science and clinical progress. Endocr Rev. 25:581-611.
- Ferris, F.L. III, (1993):** How effective are treatments for diabetic reinopathy? Am J Ophthalmol. 269:1290-1291.
- Fong, D.S.; Barton, F.B. and Bresnick, G.H. (2005):** Impaired color vision associated with diabetic retinopathy: Am J Ophthalmol. 128 : 612-7.
- Frank, R.N. (1994):** The aldose reductase controversy. Diabetes. 45(2): 169-72.
- Funatsu, H.; Yamashita, H.; Ikeda, T.; Minura, T.; Eguchi, S. and Hori, S. (2003):** Vtreous Levels of interleukin 6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 110:1698-1696.

- Funatsu, H.; Yamashita, H.; Sakata, K.; et al (2005):** Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. *Ophthalmology*. 112:806-816.
- Gandorfer, A.; Messmer, E.M.; Ulbig, M.W. and Kampik, A. (2000):** Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. *Retina*. 20: 126-33.
- Gass, J.D. (1997):** Stereoscopic atlas of macular diseases, diagnosis, and treatment, chapter 1 “normal macula” 4th edition, vol. (1); 1-18.
- Gass, J.D.; Anderson, D.R. and Davis, E.B. (1985):** A clinical, fluorescein angiographic, and electron microscopic correlation of cystoid macular edema. *Am J Ophthalmol*. 15; 100(1): 82-6.
- Gillies, M.C.; Sutter, F.K.; Simpson, J.M.; Larsson, J.; et al (2006):** Intravitreal triamcinolone for refractory diabetic macula edema. Two-year results of a double-masked, placebo-controlled, randomized clinical trial. *Ophthalmology*. 113(9): 1533-8.
- Golubovic-Arsovska, M. (2006):** Correlation of diabetic maculopathy and level of diabetic retinopathy. *Prilozi*. 2006 Dec; 27(2): 139-50.
- Guyer, D.R.; D’Amico, D.J. and Smith, C.W. (1992):** Subretinal fibrosis after laser photocoagulation for diabetic macular edema. *Am J Ophthalmol*. 113: 652-6.
- Guyot-Argenton, C. and El Maftouhi, A. (2004):** Failure of photocoagulation therapy for diabetic macular edema. *J Fr Ophthalmol*. 27:597-603.
- Hamilton, A.M.; Ulbig, M.W. and Polkinghome, P. (1996):** Classification and treatment of diabetic maculopathy. In: *Management of diabetic retinopathy*. *Br J Ophthalmol*. 80: 157-201.
- Haritoglou, C.; Kook, D.; Neubauer, A.; et al (2006):** Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina*. 26:999-1005.

- Hee, M.R.; Izatt, J.A.; Swanson, E.A.; Huang, D.; Schuman, J.S.; Lin, C.P.; Puliafito, C.A. and Fujimoto, J.G. (1995):** Optical coherence tomography of the human retina. *Arch Ophthalmol.* 113: 325-332.
- Henricsson, M.; Sellman, A.; Tyrberg, M. and Groop, L. (1999):** Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. *Acta Ophthalmol.* Apr; 77(2): 218-23.
- Ho, T.C.; Lai, W.W. and Lam, D.S. (2006):** Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. *Am J Ophthalmol.* 141 (4): 786-787.
- Hoye, V.J.; Berrocal, A.M.; Hedges, T.R. and Amaro-Quireza, M.L. (2001):** Optical coherence tomography demonstrates subretinal macular edema from papilledema. *Arch Ophthalmol.* 119: 1287-90.
- Jack, J. and Kanski, (2007):** Clinical ophthalmology 6th edition. Acquired macular disorders, introduction: 627-629.
- Jack, J. and Kanski, (2007):** Clinical Ophthalmology 6th edition. Retinal vascular diseases, Diabetic Retinopathy: 2007; 566-573.
- Jaffe, N.; Jaffe, M. and Jaffe, G. (1997):** Cystoid macular edema in cataract surgery and its complication, 6th edition. Mosby Co. St louis.: 319-33.
- Jeddi Blouza, A.; Khayati, L.; Malouche, N.; Slim, B.; Azeiz, S. and Zouari, B. (2005):** Risk factors for diabetic macular edema *J Fr Ophthalmol.* 2005; 28 (10): 1033-8.
- Jeppesen, P. and Bek, T. (2006):** Impaired retinal autoregulation in small retinal arterioles before and after focal laser treatment for diabetic maculopathy. *Br J Ophthalmol.* 90: 198-201.
- Jonas, J.B.; Martus, P.; Degenring, R.F.; Kreissig, I. and Akkoyun, I. (2005):** Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. *Arch Ophthalmol.* 123: 1338-43.

- Jonas, J.B.; Degenring, R.F.; Kreissig, I.; et al (2005):** Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. *Ophthalmology*. 112:593-598.
- Jonas, J.B.; Spandau, U.H.; Kamppeter, B.A.; Vossmerbaeumer, U.; Harder, B. and Sauder, G. (2006):** Repeated intravitreal high-dosage injection of triamcinolone acetonide for diffuse diabetic macular edema. *Ophthalmology*. 113: 800-804.
- Jonas, J.B. (2005):** Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. *Acta Ophthalmol Scand*. Dec; 83(6): 645-663.
- Jonas, J.B.; Hayler, J.K.; Sofker, A.; et al:** Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol* 2001; 131: 468-71.
- Jonas, J.B.; Kreissig, I.; Sofker, A. and Degenring RF:** Intravitreal injection of triamcinolone for diffuse diabetic macular edema. *Arch Ophthalmol*. 2003; 121: 57-61.
- Jonas, J.B.; Kreissig, I.; Spandau, U.H. and Harder B (2006):** Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. *Am J Ophthalmol*. 141 (3): 579-80.
- Joussen, A.M.; Smyth, N. and Niessen, C. (2007):** Pathophysiology of diabetic macular edema. *Dev Ophthalmol*. 39: 1-12.
- Kang, S.W.; Sa, H.S.; Cho, H.Y. and Kim, J.I. (2006):** Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. *Arch Ophthalmol*. 124: 653-8.
- Kang, S.W.; Park, C.Y. and Ham, D.I. (2004):** The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular oedema. *Am J Ophthalmol*. 137: 313-322.
- Karacorlu, M.; Ozdemir, H.; Karacorlu, S.; Alacali, N.; Mudun, B. and Burumcek, E. (2005):** Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. *Eye*. 2005; 19: 382-6.

- Kaushik, S.; Gupta, V.; Gupta, A.; Dogra, M.R. and Singh, R. (2004):** Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. *Am J Ophthalmol.* 137(4): 758-760.
- Kim, S.Y. Sanislo, S.R.; Dalal, R.; et al. (1996):** The selective effect of micropulse diode laser upon the retina. *Invest Ophthalmol Vis Sci.* 37 (3, suppl).
- Kim, B.Y.; Smith, S.D. and Kaiser, P.K. (2006):** Optical coherence tomographic patterns of diabetic macular oedema. *Am J Ophthalmol* 142: 405-412.
- Krzystolik, M.G.; Filippopoulos, T.; Ducharme, J.F. and Loewenstein, J.I. (2006):** Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. *Arch Ophthalmol.* 124: 920-921.
- Kumagai, K.; Ogino, N.; Furukawa, M.; et al (2002):** Internal limiting membrane peeling in vitreous surgery for diabetic macular edema *Nippon Ganka Gakkai Zasshi.* 106: 590-594.
- Lam, R.F.; Lai, W.W.; Chan, W.M.; Liu, D.T. and Lam, D.S. (2006):** Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. *Ophthalmologica.* 220: 206.
- Laursen, M.L.; Moeller, F.; Sander, B. and Sjoelie, A.K. (2004):** Subthreshold micropulse diode laser treatment in diabetic macular edema *Br J Ophthalmol.* 88: 1173-1179.
- Leal, E.C.; Manivannan, A.; Hosoya, K.; et al (2007):** Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 48: 5257-5256.
- Lewis, H.; Abrams, G.W.; Blumenkranz, M.S. and Campo, R.V. (1992):** Vitrectomy for diabetic macular traction and edema associated with posterior hyalodial traction. *Ophthalmology.* 99: 753-759.
- Lewis, H.; Schachat, A.P.; Haimann, M.H.; et al (1990):** Choroidal neovascularization after laser photocoagulation for diabetic macular edema. *Ophthalmology.* 97: 503-10.

- Lim, L.L.; Smith, J.R. and Rosenbaum, J.T. (2005):** Retisert (Bausch & Lomb/Control Delivery Systems). *Curr Opin Investig Drugs*. 6: 1159-1167.
- Luttrull, J.K.; Musch, D.C. and Mainster, M.A. (2005):** Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. *Br J Ophthalmol* 89: 74-80.
- Martidis, A.; Duker, J.S.; Greenberg, P.B.; Rogers, A.H.; Puliafito, C.A.; Reichel, E. and Bauman, C. (2002):** intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 109: 920-7.
- Massin, P.; Girach, Erginay, A. and Gaudric, A. (2006):** Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. *Acta Ophthalmol Scand*. 2006; 84: 466-474.
- Massin, P.; Audren, F.; Haouchine, B.; Erginay, A.; Bergmann, J.F.; Benosman, R.; Caulin, C. and Gaudric, A. (2004)::** Intravitreal triamcinolone acetate for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. *Ophthalmology*. 111: 218-24.
- Massin, P.; Duguid, G.; Erginay, A.; Haouchine, B. and Gaudric, A. (2003):** Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. *Am J Ophthalmol*. 135: 169-177.
- Matsunaga, N.; Ozeki, H.; Hirabayashi, Y.; Shimada, S. and Ogura, Y. (2005):** Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. *Retina*. 25: 311-316.
- Matsuo, T. (2006):** Disappearance of diabetic macular hard exudates after hemodialysis introduction. *Acta Med Okayama*. 60(3): 201-5.
- McCuen, B.W.; Bessler, M.; Tano, Y.; Chandler, D. and Machemer, R. (1981):** The lack of toxicity of intravitreally administered triamcinolone acetate. *Am J Ophthalmol*. 91: 785-788.

- Michael, W. (2006):** Stewart: Pharmacotherapy (IVTA/AVASTIN) as first-Line Treatment for DME. Retinal physicians. May.
- Mochizuki, Y.; Hata, Y.; Enaida, H.; et al (2006):** evaluating adjunctive surgical procedures during vitrectomy for diabetic macular edema. Retina, 26:143-148.
- Mohamed, K. and Tameesh, (2006):** Correlation of the tomographic viteromacular features with the outcomes of laser treatment in cases of diffuse diabetic macular edema. Bull Ophthalmol Soc Egypt. 99, Number 4.
- Morbidelli, L.; Donnini, S. and Ziche, M. (2003):** Role of nitric oxide in the Modulation of angiogenesis. Curr Pharm.9,521-530.
- Moshfeghi, D.M.; Kaiser, P.K.; Scott, I.U.; Sears, J.E.; Benz, M.; Sinesterra, J.P.; Kaiser, R.S.; Bakri, S.J.; Maturi, P.K.; Belmont, J.; Beer, P.M.; Murray, T.G.; Quiroz-Mercado, H. and Mieler, W.F. (2003):** Acute endophthalmitis following intravitreal triamcinolone acetanide injection.. Am J Ophthalmol. 136: 791-796.
- Moshfeghi, D.M.; Scott, I.U.; Flynn, H.W. and Puliafito, C.A. (2004):** Pseudohypopyon after intravitreal triamcinolone acetanide injection for cystoid macular edema. Am J Ophthalmol. 138: 489-492.
- Muscat, S.; Parks, S.; Kemp, E.; et al (2002):** Repeatability and reproducibility of macular thickness measurements with the Humphrey OCX system. Invest Ophthalmol Vis Sci. 43: 490-495.
- Olk, R.J. (1986):** Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 93: 938-50.
- Olk, R.J. (1990):** Argon green (514nm) versus krypton red (647nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 97 (9): 1101-12.
- Olk, R.J. and Lee, C.M. (1994):** Diabetic retinopathy, practical management of diabetic macular edema. Papadopoulos D, Lippincott JB Co, Piladelphia : 51-83.

- Oshima, Y.; Emi, K.; Yamanishi, S. and Motokura, M. (1999):** Quantitative assessment of macular thickness in normal subjects and patients with diabetic retinopathy by scanning retinal thickness analyzer. *Br J Ophthalmol.* 83: 54-61.
- Otani, T. and Kishi, S. (2007):** Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. *Ophthalmology.* 114:104-107.
- Otani, T.; Kish, S. and Maruyama, Y. (1999):** Patterns of diabetic macular edema with optical coherence tomography. *Am J Ophthalmol.* 127: 688-693.
- Ozdemir, H.; Karacorlu, M. and Karacorlu, S.A.(2005):** Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema. *Am J Ophthalmol.* 140: 251-255.
- Pandya NM, Dhalla NS, Santani DD:** Angiogenesis a new Target for future Therapy. *Vascul. Pharmacol.* 2006; 44,265-274.
- Panozzo, G.; Parolini, B.; Gusson, E.; Mercanti, A.; Pinackatt, S.; Bertoldo, G. and Pignatto, S. (2004):** Diabetic macular edema: an OCT-based classification. *Semin Ophthalmol.* 19: 13-20.
- Paques, M.; Massin, P.; Sahel, J.A.; Gaudric, A.; Bergmann, J.F.; Azancot, S.; Levy, B.I. and Vicaut, E. (2005):** diurnal fluctuations of macular edema in patients with morning vision blurring: correlation with arterial pressure and effect of light deprivation. *Invest Ophthalmol Vis Sci.* 6 (1): 4707-11.
- Parolinim, Panozzo, G.; Gusson, E.; et al (2004):** Diode laser, vitrectomy and intravitreal triamcinolone: A comparative study for the treatment of diffuse non tractional diabetic macular edema. *Semin Ophthalmol.* 19:1-12.
- Patel, J.I.; Hykin, P.G.; Schadt, M.; Luong, V. and Gregor, Z.J. (2006):** Pars Plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. *Retina.* 26:5-13.
- Polito, A.; Del Borrello, M.; Isola, M.; Zemella, N. and Bandello, F. (2005):** Repeatability and reproducibility of fast macular

thickness mapping with Stratus optical coherence tomography. Arch Ophthalmol. 123: 1330-7.

- Polito, A.; Del Borrello, M.; Polini, G.; Furlan, F.; Isola, M. and Bandello, F. (2006):** Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT. Retina. 26 (1): 14-20.
- Polito, A.; Shah, S.M.; Haller, J.A.; Zimmer-Galler, I.; Zeimer, R. Campochiaro, P.A. and Vitale, S. (2002):** Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol. 2002 Aug; 134(2): 240-51.
- Roesnfeld, P.J.; Brown, D.M.; Heier, J.S.; et al (2006):** "Ranibizumab for neovascular age-related macular degeneration," New England Journal of Medicine, vol. 355, no. 14, pp. 2006;1419-1431.
- Roider, J.; Brinkmann, R.; Wirbelauner, C.; et al (2000):** Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol. 84: 40-7.
- Roth, D.B.; Chieh, J.; Spurn, M.J.; Chaudhry, N.A.; et al (2003):** Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 121: 1279-82.
- Rudnisky, C.J.; Hinz, B.J.; Tennant, M.T.; de Leon, A.J. and Greve, M.D. (2002):** High-resolution stereoscopic digital fundus photography versus contact lens biomicroscopy for the detection of clinically significant macular edema. Ophthalmology. 109 (2): 267-74.
- Sakamoto, T.; Enaida, H.; Kubota, T.; et al (2004):** Incidence of acute endophthalmitis after triamcinolone-assisted pars plana vitrectomy. Am J Ophthalmol. 138: 137-138.
- Sakamoto, T.; Miyazaki, M.; Hisatomi, T.; et al., (2002):** Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decrease the postoperative blood-

ocular barrier breakdown. Graefe's Arch Clin Exp Ophthalmol. 240: 423-429.

Sander, B.; Larsen, M.; Thrane, L.; Hougaard, J.L. and Jorgensen, T.M. (2005): Enhanced optical coherence tomography imaging by multiple scan averaging. Br J Ophthalmol. 89: 207-212.

Scholes, G.N.; O'Brien, W.J.; Abrams, G.W. and Kubicek, M.J.F. (1985): Clearance of triamcinolone from vitreous. Arch Ophthalmol. 103: 1567-1569.

Sebag, J. and Balazes, E.A. (1984): Pathogenesis of cystoid macular edema: an anatomic consideration of vitreoretinal adhesions. Ophthalmology. 91: 493-498.

Seenu, M.H. and Gaurav, K.S. (2005): An Alternative to Dyes for ILM Peeling. Triamcinolone acetonide may be a cost-effective adjuvant in vitreoretinal surgery and an excellent alternative to ICG or Trypan Blue. Review of Ophthalmol Vol. No. 12, Issue:.

Shah, S.P. and Laidlaw, D.A. (2006): Vitrectomy for diabetic macular edema. Am J Ophthalmol. 141: 225.

Shah, S.P.; Patel, M.; Thomas, D.; Aldington, S. and Laidlaw, D.A. (2006): Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol. 90: 33-36.

Sigelman, J. (1980): Diabetic macular edema in juvenile-and adult-onset diabetes. Am J Ophthalmol. 90(3): 287-96.

Simo, R.; Hernandez, C. and Carrasco, E. (2006): Angiogenic and anti-angiogenic factors in proliferative Diabetic retinopathy. Curr. Diabetes Rev.; 71-98.

Sonoda, K.; Sakamoto, T.; Enaida, H.; et al (2004): Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreal triamcinolone acetonide. Ophthalmology. 111: 226-230.

Stefánsson, E. and Landers, M.B. (2006) : How does vitrectomy affect diabetic macular edema? Am J Ophthalmol. 141: 984.

- Stefansson, E.; Novack, R.L. and Hatchell, D.L. (1990):** Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. *Invest Ophthalmol Vis Sci.* 31: 284-289.
- Sutter, F.K.; Simpsa, J.M. and Gillies, M.C. (2004):** Intravitreal triamcinolone for diabetic macular edema that persist after laser treatment: three month efficacy and safety results of prospective, randomized, double-masked, placebo-controlled clinical trial. *Ophthalmology.* 111: 2044-9.
- Tachi, N. and Ogino, N. (1996):** Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. *Am J Ophthalmol.* 122(2): 258-60.
- Takegi, H.; Koyama, S.; Seike, H.; Oh, H.; Otani, A.; Matsumura, M.; et al:** Potential Role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization, *Invest Ophthalmol Vis Sci.*44: 393-402.
- Tamura T, Hirakata A, Oda H, et al. (2005):** Outcome of vitreous surgery with internal limiting membrane peeling for diabetic macular edema. *Jpn Rev Clin Ophthalmol.* 97: 979-982.
- Tarnos, P.G.; Wickremasinghe, S.S.; Stangos, N.T.; Topouzis, F. and Tsinopoulos, I. (2004):** Macular Edema. *Surv ophthalmol.* 49:470-490.
- Verma, L.K.; Vivek, M.B.; Kumar, A.; Tewari, H.K. and Venkatesh, P. (2004):** A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. *J Ocular Pharmacol Ther.* 20:227-284.
- Viola, F.; Morescalchi, F. and Staurenghi, C. (2006):** Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. *Arch Ophthalmol.*124 (1): 133-4.
- Wael Soliman, Sander, B. and Jrgensen, T.M. (2007):** Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. *Acta Ophthalmol Scand.* 85(6): 613-7.

- Walton, K.A.; Meyer, C.H.; Harkrider, C.J.; Cox, T.A. and Toth, C.A. (2002):** Age-related changes in vitreous mobility as measured by video B scan ultrasound. *Exp eye Res.* 74: 173-180.
- Weiner, A.; Christopoulos, V.A.; Gussler, C.H.; et al (1997):** foveal cone function in non proliferative diabetic retinopathy and Macular edema. *Invest ophthalmol vis sci.* 38:1443-1449.
- Williams, R.; Airey, M.; Baxter, H.; Forrester, J.; Kennedy-Martin, T. and Girach, A. (2004):** Epidemiology of diabetic retinopathy and macular oedema: a systematic review. *Eye.* 18 (10): 963-83.
- Yamamoto, T.; Akabane, N. and Takeuchi, S. (2001):** Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. *Am J Ophthalmol.* 132(3): 369-77.
- Yanoff, M. and Duker, J.S. (2003):** Diabetic macular edema ophthalmology (second edition). Vol. 8, 101: 779-785.
- Yu, D.Y.; Cringle, S.J.; Su, E.; Yu, P.K.; Humayun, M.S. and Dorin, G. (2005):** Laser-Induced Changes in Intraretinal Oxygen Distribution in Pigmented Rabbits. *Invest Ophthalmol Vis Sci.* 46: 988-999.
- Zein, W.M.; Nouredin, B.N.; Jurdi, F.A.; Schakal, A. and Bashshur, Z.F. (2006):** Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinaopathy with macular edema. *Retina.* 26: 137-142.